-
On the second anniversary of the "dual carbon" goal, how can Chinese pharmaceutical companies move towards carbon neutrality?
Time of Update: 2023-01-06
For Chinese pharmaceutical companies, judging and adapting to the specific impacts of climate change on their business and industrial chains, and promoting the sustainability of carbon reduction measures by improving resilience and resilience, is an important starting point for them to achieve their long-term carbon neutrality goals.
-
The moment of change: when more and more innovative pharmaceutical companies come out of the involvement
Time of Update: 2023-01-06
On November 10, APL-1401, the world's first investigational drug for the treatment of IBD (inflammatory bowel disease) with neurotransmitters, was approved by the FDA for clinical trial, which is a microcosm of the upward process of the innovative drug industry.
-
The first domestic desulsumab injection "flower" this! Two products landed in two years, and the commercialization of Boan Biotech stabilized
Time of Update: 2023-01-06
The pharmacin circle learned that on the evening of November 10, Luye Pharmaceutical Group announced that its holding subsidiary Boan Biotech's denosumab injection (Boyoube ®) was approved for the tre
-
Heavy! Merck announced that the 10th indication of K drug was approved in China for the treatment of triple-negative breast cancer
Time of Update: 2023-01-06
On November 9, Merck announced that its PD-1 inhibitor, pembrolizumab, has been approved by the National Medical Products Administration (NMPA) of China in combination with chemotherapy neoadjuvant therapy and continues to be pembrolizumab monotherapy after surgery for the treatment of patients with early-stage high-risk triple-negative breast cancer (TNBC) with a well-validated assay to evaluate patients with PD-L1 (composite positive score (CPS) ≥20).
-
The sixth batch of national mining has been implemented for half a year, and domestic enterprises are facing difficulties in quantity
Time of Update: 2023-01-06
Domestic insulin companies are more difficult than all parties think with the help of national procurement and release. 01 Insulin national mining for half a year01 Insulin national mining for half a
-
The sixth batch of national mining has been implemented for half a year, and domestic enterprises are facing difficulties in quantity
Time of Update: 2023-01-06
Domestic insulin companies are more difficult than all parties think with the help of national procurement and release. 01 Insulin national mining for half a year01 Insulin national mining for half a
-
With the intensification of changes in China's pharmaceutical market, the investment layout mode of multinational pharmaceutical companies is changing
Time of Update: 2023-01-06
It is reported that during the recent Expo, a large number of multinational pharmaceutical companies are laying out in China from improving the supply chain system, to serving users' chronic disease management, to the research and development and landing of innovative drugs.
-
Clinical trial results made public: The National Institutes of Health began taking action against academic institutions that did not comply with reporting requirements
Time of Update: 2023-01-06
Of the 37 researchers who did not comply with the reporting requirements, 21 New NIH-funded clinical trials were initiated before the latest results from previous clinical trials were submitted to ClinicalTrials.
-
Generic drugs have no "money" way? The global giants spun off by MNC increased innovation, and Chinese pharmaceutical companies gave up overtaking opportunities to transform
Time of Update: 2023-01-06
01 Hui Zhi began to harvest innovative pharmaceutical companiesHui Zhi began to harvest innovative pharmaceutical companiesOn November 7, generic drug giant Hui Zhi broke the news that the company agreed to buy Oyster Point at a cash price of $11 per share of all shares outstanding, for a total consideration of approximately $295 million.
-
Which PD-1 "Four Tigers" is stronger? Hengrui is secretive, Baekje is temporarily ahead, and new players should not be underestimated
Time of Update: 2023-01-06
BeiGene: PD-1 tislelizumab in the third quarter continued to increase sales of 879 million yuan In addition to Hengrui Pharmaceutical's "secret", as the earliest PD-1 product listed in China, Baizean's ® performance is currently in a leading position, and the number of approved indications is also among the best.
-
Tens of thousands down to 2000? A collective procurement of "collective failure of domestic production"
Time of Update: 2023-01-06
On November 7, the Jilin Provincial Public Resources Trading Center issued the "Spring Roil Medical Consumables Interprovincial Alliance Centralized Procurement Document", with Jilin leading the "Spri
-
Under the catch up of domestic machinery enterprises, multinational giants amplify their moves
Time of Update: 2023-01-06
How supply chain assurance is achievedHow supply chain assurance is achievedMedical devices have strong manufacturing attributes, and Chinese enterprises have advantages in manufacturing costs, industrial supply chain support, engineer dividends and other aspects, China's medical device industry from imitation gradually to independent innovation, domestic upgrading and overseas export breakthroughs are promising, the future must be oriented to the global market.
-
With new drug applications suspended, what are the challenges for gene editing therapy to go to the clinic?
Time of Update: 2023-01-06
The birth of the gene-editing technology CRISPR-Cas9 in 2012 brought mankind's dream of curing genetic diseases through gene editing closer and led to an unprecedented boom in the development and inve
-
What was the financing situation in the pharmaceutical and health sector in November? A number of pharmaceutical companies raised more than 100 million yuan in a single financing
Time of Update: 2023-01-06
Keyi Pharmaceutical Recently, Keyi Pharmaceutical also announced the completion of the first round of financing of nearly 500 million yuan, invested by Kequan Fund established by Zhejiang Anji Development Zone.
-
More than 10 innovative drug companies have completed a new round of financing, which therapeutic areas are they targeting?
Time of Update: 2023-01-06
Public information shows that since November, Chinese companies in the field of innovative drug research and development have ushered in a lot of financing progress. From the perspective of research f
-
What is the impact of the mixed test fee exceeding 3 yuan per time in many places, and the price of nucleic acid testing has reached a new low?
Time of Update: 2023-01-06
On November 8, Guizhou Province's disease control and testing institutions and public medical institutions began to implement new nucleic acid testing prices, and the maximum fee for a single test was adjusted to 14 yuan per person; The maximum fee for multi-person mixed testing (including large-scale screening and normalized testing organized by the government) is adjusted to 2.
-
Pharmaceutical companies are accelerating the development of new indications, and competition in this area is fierce
Time of Update: 2023-01-06
At present, large pharmaceutical companies at home and abroad attach great importance to the development of new indications of innovative drugs, and are continuously expanding the field of drug use.
-
Pharmaceutical companies are accelerating the development of new indications, and competition in this area is fierce
Time of Update: 2023-01-06
At present, large pharmaceutical companies at home and abroad attach great importance to the development of new indications of innovative drugs, and are continuously expanding the field of drug use.
-
Exclusive interview with Ren Feng: Behind the $1.2 billion major cooperation, why is Insilico favored by Sanofi?
Time of Update: 2023-01-06
Arterial New Medicine learned for the first time that on November 8, Insilico, a clinical-stage drug discovery company driven by artificial intelligence (AI), announced a multi-year drug development collaboration with Sanofi that will last for many years and target multiple targets.
-
The "medicine king" laurels will eventually change hands, but innovation will not die
Time of Update: 2023-01-06
Sanofi leads, Hengrui, Baekje, Roche, Merck layout, "organoids" have become a must for global R&D!; MedTrend Medical Trends In Evaluate In a report by Pharma, Humira is no longer on the list of the top 10 best-selling drugs in the world in 2028, but Skyrizi and Imbruvica, also from AbbVie, are among them.
